Clinical Topics   /   Oncology

Cabozantinib Improves Survival in Liver Cancer Regardless of Age

by Annette Boyle
June 1, 2018

HOUSTON — For veterans with hepatocellular carcinoma (HCC), research presented today at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago offers encouraging the news. The study determined that a new tyrosine kinase inhibitor (TKI) significantly improves progression free and overall survival patients with HCC in both young and older patients.1

That’s significant because most cases of HCC at the VA develop following decades of infection with hepatitis C virus, so veterans tend to be over 65 when diagnosed. Veterans also develop the disease at about five times the rate seen in the general population. The number of veterans with HCC has steadily risen from about 500 in 2002 to 4,900 in 2013 to more than 8,000 in 2017, according to the VA.

While nearly all veterans who have been diagnosed with HCV will have been offered curative treatment with direct acting antivirals, those who had cirrhosis at the time of treatment may still go on to develop HCC, according to Jennifer Kramer, PhD, MPH, an investigator with the Clinical Epidemiology & Comparative Effectiveness Program, Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center in Houston.

The phase III CELESTIAL study of 707 patients who had previously received system treatment for advanced hepatocellular carcinoma found that cabozantinib improved median overall survival by 25% and median progression free survival from 1.9 months to 5.2 months, a risk reduction of 56%. Cabozantinib is a TKI that targets VEGF, MET and TAM receptors. The median age of study participants was 64 years.

When investigators broke down the results by age, they found no significant difference in median progression free survival between patients 65 or older and those younger than 65; both groups saw about a 55% improvement with cabozantinib compared to placebo. Patients receiving placebo who were 65 or older had a median overall survival of 7.7 months, while younger patients had a median overall survival of 8.3 months for placebo. Median overall survival in the older group was 9.6 months and 11.1 months in the younger group for cabozantinib.

Older patients had twice the discontinuation on cabozantinib than younger patients, but both groups had similar rates of dose reduction and similar median average daily dose of cabozantinib.


1Rimassa L, Cicin I, Blanc JF, et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. J Clin Oncol 36, 2018 (suppl; abstr 4090).

Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


U.S. Medicine Recommends


More From oncology

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Oncology

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

[wpdevart_facebook_comment curent_url=" http://www.usmedicine.com/clinical-topics/oncology/cabozantinib-improves-survival-in-liver-cancer-regardless-of-age/ " order_type="social" title_text="Facebook Comment" title_text_color="#000000" title_text_font_size="22" title_text_font_famely="monospace" title_text_position="left" width="100%" bg_color="#d4d4d4" animation_effect="random" count_of_comments="3" ]

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up